Parallel Industries Inc. (EAPH) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerParallel Industries Inc. (EAPH) trades at $0.00002. Parallel Industries Inc. (EAPH) is a Toronto-based healthcare company focused on developing topical medications for cancer and other medical conditions. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for EAPH: EAPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Parallel Industries Inc. (EAPH) Healthcare & Pipeline Overview
Parallel Industries Inc. is a healthcare company specializing in the development of topical medications, with a historical focus on cancer treatments and a commitment to the pharmaceutical process from development to marketing.
What Is the Investment Thesis for EAPH?
Parallel Industries Inc. presents a unique case within the healthcare sector, particularly in the specialty and generic drug manufacturing industry. The company's historical focus on topical medications for cancer treatment positions it well in a market that is increasingly leaning towards innovative therapeutic solutions. The global cancer therapeutics market was valued at approximately $150 billion in 2021 and is projected to grow at a CAGR of around 7% through 2028. However, the company currently lacks substantial operational activities, which raises concerns regarding its immediate financial viability. Investors should monitor any developments regarding potential product launches or strategic partnerships that could revitalize the company's operations. The absence of a dividend and a high beta of 27.13 indicate significant volatility and risk, making it essential for investors to conduct thorough due diligence before considering any investment.
Based on FMP financials and quantitative analysis
EAPH Key Highlights
Market Cap: $0.00B, indicating minimal operational activity and market presence.
- Beta: 27.13, suggesting extreme volatility compared to the broader market.
- Dividend Yield: None, reflecting the company's lack of current profitability.
- Employee Count: 6, indicating a very small operational scale.
- Rebranded in December 2020 from Easton Pharmaceuticals Inc., marking a strategic shift.
Who Are EAPH's Competitors?
EAPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| PFE Pfizer Inc. | $27.41 | -1.40% | $158B | 68 5-pillar |
| JNJ Johnson & Johnson | $252.93 | -1.21% | $617B | 90 5-pillar |
| MRK Merck & Co., Inc. | $139.54 | -3.30% | $356B | 75 5-pillar |
| BMY Bristol-Myers Squibb Company | $58.81 | -3.83% | $125B | 92 5-pillar |
| AMGN Amgen Inc. | $402.98 | -0.01% | $218B | 84 5-pillar |
| AKAN Akanda Corp. | $1.91 | -3.54% | — | |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.59 | +42.55% | $7.59M | — |
| BFRI Biofrontera Inc. | $0.89 | -12.23% | $13.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EAPH's Key Strengths?
Historical expertise in topical medication development.
- Niche focus on cancer treatment options.
- Potential for strategic partnerships in drug development.
- Rebranding may enhance market perception.
What Are EAPH's Weaknesses?
Currently lacks substantial business operations.
- Minimal market capitalization indicating limited liquidity.
- Small employee base may hinder operational capacity.
- High beta suggests significant volatility and risk.
What Are the Key Risks for EAPH?
Financial-distress signal — its Altman Z-Score of -5.09 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-2.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant volatility due to low market capitalization and OTC classification.
- Limited operational activities may hinder growth prospects.
- Regulatory challenges could delay product development and approvals.
- Intense competition from established pharmaceutical companies.
What Are EAPH's Competitive Advantages?
- Historical expertise in drug development and commercialization.
- Potential for niche market positioning within topical cancer treatments.
- Ability to leverage partnerships for research and product development.
- Rebranding efforts may enhance market perception and attract new opportunities.
- Focus on innovative therapeutic solutions aligns with industry trends.
What Does EAPH Do?
Founded in 1997, Parallel Industries Inc., originally known as Easton Pharmaceuticals Inc., is headquartered in Toronto, Canada. The company initially focused on developing and commercializing various topically applied medications aimed at treating cancer, alongside other therapeutic solutions for a range of medical conditions. Over the years, Parallel Industries has emphasized a comprehensive approach to the pharmaceutical process, which includes development, licensing, manufacturing, and marketing of both prescription and over-the-counter products. In December 2020, the company rebranded to Parallel Industries Inc., marking a new chapter in its operational strategy. Currently, Parallel Industries does not conduct substantial business operations, leading to a minimal market capitalization and limited liquidity. Despite these challenges, the company retains a potential strength in its historical expertise within the healthcare sector, particularly in drug development and commercialization. With only six employees, the company is small but retains the potential for growth should it choose to re-enter the market with new products or partnerships.
What Products and Services Does EAPH Offer?
- Develops topical medications aimed at treating cancer and other medical conditions.
- Engages in the pharmaceutical process from development to marketing.
- Previously focused on both prescription and over-the-counter products.
- Operates within the healthcare sector with a historical emphasis on drug commercialization.
- Rebranded in 2020 to signify a strategic shift in operations.
- Currently has minimal operational activities and market presence.
How Does EAPH Make Money?
- Generates revenue through the development and commercialization of pharmaceutical products.
- Focuses on both prescription and over-the-counter medication markets.
- Engages in licensing agreements for drug development and marketing.
- Utilizes a comprehensive approach to the pharmaceutical process, from R&D to market launch.
- Potential for revenue generation through partnerships and collaborations in drug development.
What Industry Does EAPH Operate In?
The drug manufacturing industry, particularly in the specialty and generic segments, is experiencing significant growth driven by increasing healthcare expenditures and a rising prevalence of chronic diseases, including cancer. The global market for cancer therapeutics is projected to grow at a CAGR of 7%, reflecting strong demand for innovative treatment options. Parallel Industries Inc. operates in a competitive landscape that includes established players with robust portfolios and extensive distribution networks. The company's historical focus on topical medications may provide niche opportunities, but it faces challenges in re-establishing itself amid larger, more resourceful competitors.
Who Are EAPH's Key Customers?
- Healthcare providers and medical professionals seeking innovative treatment options.
- Patients requiring topical medications for cancer and other conditions.
- Pharmacies and healthcare institutions that distribute pharmaceutical products.
- Research institutions interested in partnerships for drug development.
- Regulatory bodies involved in the approval and oversight of pharmaceutical products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Parallel Industries Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Evan Karras. EAPH has traded publicly since 1999.
Key Financial Metrics
Return on equity for Parallel Industries Inc. stands at -2.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.9%, showing how much profit it generates from its asset base. A current ratio of 0.69 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Parallel Industries Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.09 places it in the distress zone, a signal of elevated financial risk.
EAPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
EAPH Latest News
No recent news available for EAPH.
EAPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EAPH.
Price Targets
Wall Street price target analysis for EAPH.
EAPH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EAPH; grades run from A+ (80-100) to F (below 30).
Leadership: Evan Karras
CEO
Evan Karras has a diverse background in healthcare management and pharmaceutical development. He has been instrumental in guiding Parallel Industries through its rebranding and strategic shifts. Karras has extensive experience in navigating the complexities of the pharmaceutical industry, having held various leadership roles in both startup and established companies. His educational background includes a degree in pharmaceutical sciences, equipping him with the knowledge necessary to lead a company in this sector.
Track Record: Under Karras's leadership, Parallel Industries has rebranded to focus on its core competencies in drug development. He has emphasized the importance of strategic partnerships and innovation, aiming to position the company for future growth in the competitive pharmaceutical landscape.
EAPH OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers such as OTCQX or OTCQB. Stocks in this tier often have lower liquidity and less stringent reporting requirements, which can lead to higher volatility and risk for investors. Companies in this tier may also have limited access to capital markets.
- OTC Tier: OTC Other
- Low liquidity may result in significant price volatility.
- Limited operational activities raise concerns about financial viability.
- Potential regulatory challenges in drug development.
- Lack of transparency in financial disclosures may hinder investor confidence.
- Verify the company's financial filings and operational updates.
- Assess the management team's experience and track record.
- Monitor any regulatory developments affecting the company.
- Evaluate the competitive landscape and market positioning.
- Review potential partnerships or collaborations in drug development.
- Rebranding efforts may indicate a strategic shift towards growth.
- Historical expertise in drug development provides a foundation for future opportunities.
- Presence in the healthcare sector may attract interest from investors and partners.
EAPH Healthcare Stock FAQ
How does Parallel Industries Inc. navigate regulatory approval processes?
Parallel Industries Inc. must adhere to stringent regulatory approval processes mandated by bodies such as the FDA and Health Canada. This involves submitting comprehensive data on drug safety and efficacy, which can be a lengthy process.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited operational activities and market presence raise uncertainties about the company's future.